August 26, 2021
Zydus Pharmaceuticals Inc. moved Wednesday to appeal the dismissal of its antitrust counterclaims accusing Takeda Pharmaceutical Co. Ltd. of filing sham patent litigation to delay competition for heartburn medication Prevacid.
July 26, 2021
A New Jersey federal judge on Monday tossed generic-drug maker Zydus Pharmaceuticals Inc.'s antitrust counterclaims accusing Takeda Pharmaceutical Co. Ltd. of filing sham patent litigation to delay competition for heartburn medication Prevacid, ruling there was no showing Takeda didn't have legitimate infringement concerns.
June 06, 2019
A New Jersey federal judge isn't buying Takeda Pharmaceutical Co.'s argument that it believes it is entitled to attorney-client privilege from Baker Botts after the law firm represented the drugmaker's co-plaintiff in a previous patent case.
January 14, 2019
Baker Botts LLP can continue representing Zydus Pharmaceuticals as it pursues antitrust claims against Takeda over a heartburn medication, despite the law firm's prior representation of Takeda's ally in patent litigation over the same drug, a New Jersey federal judge said in a ruling made public Friday.
December 20, 2018
Patent infringement lawsuits challenging generic drug applications aren't automatically immune from antitrust claims, a New Jersey federal judge ruled Wednesday, refusing to toss counterclaims accusing Takeda Pharmaceutical Co. Ltd. of trying to illegally maintain its monopoly on a heartburn therapy with "sham" infringement claims.
June 05, 2018
Generic-drug maker Zydus on Monday urged a New Jersey federal judge to reject rival Takeda's bid to dodge antitrust counterclaims in a patent infringement suit over a generic for the dissolving heartburn relief tablet Prevacid SoluTab.